307512-24-9

Basic information

• Product Name: 5-(4-BROMO-PHENYL)-3H-THIENO[2,3-D]PYRIMIDIN-4-ONE
• Synonyms: OTAVA-BB BB0129720275;AURORA 20385;AKOS MSC-0524;5-(4-BROMO-PHENYL)-3H-THIENO[2,3-D]PYRIMIDIN-4-ONE;5-(4-BroMophenyl)thieno[2,3-d]pyriMidin-4(3H)-one;5-(4-bromophenyl)-Thieno[2,3-d]pyrimidin-4(1H)-one;5-(4-bromophenyl)-3H,4H-thieno[2,3-d]pyrimidin-4-one
• CAS NO: 307512-24-9
• Molecular Formula: C₁₂H₇BrN₂OS
• Molecular Weight: 307.17
• Mol File: 307512-24-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-(4-BROMO-PHENYL)-3H-THIENO[2,3-D]PYRIMIDIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-BROMO-PHENYL)-3H-THIENO[2,3-D]PYRIMIDIN-4-ONE(307512-24-9)
• EPA Substance Registry System: 5-(4-BROMO-PHENYL)-3H-THIENO[2,3-D]PYRIMIDIN-4-ONE(307512-24-9)

Safety Data

• Statements: 20/21/22
• Safety Statements: 24/25-36/37
• Hazardous Substances Data: 307512-24-9(Hazardous Substances Data)

Usage

Chemical Properties

Off-white solid

Upstream product

• 306934-99-6 2-amino-4-(4-bromo-phenyl)-thiophene-3-carboxylic acid ethyl ester 
• 77287-34-4 formamide 
• 99-90-1 para-bromoacetophenone 

Downstream Products

• 379241-58-4 C₁₂H₇BrN₂S₂ 
• 457908-38-2 C₁₆H₁₃BrN₂O₂S₂ 
• 457908-74-6 {[5-(4-bromophenyl)thieno[2,3-d]pyrimidin-4-yl]thio}acetic acid 

Relevant articles and documents

Identification of 4-methoxythieno[2,3-d]pyrimidines as FGFR1 inhibitors

Aim. To identify novel FGFR1 inhibitors using virtual screening approach. Methods. We used methods of organic synthesis, molecular docking via the Autodock 4.2.6 program package and in vitro biochemical tests with γ-32P. Results. In vitro experiments showed that 9 of 23 tested compounds possess inhibitory activity against FGFR1 with IC50 values in the range from 0.9 to 5.6 μM. Conclusions. Nine FGFR1 inhibitors were developed. The mode of compounds binding with the ATP-acceptor site was determined using molecular docking methods and the dependence of the compounds’ activity on the substituents R1, R4 and R5 was evaluated.

Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin- 4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2

A novel series of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids has been synthesized and tested in vitro towards human protein kinase CK2. It was revealed that the most active compounds inhibiting CK2 are 3-{[5-(4-methylphenyl)thieno[2,3-d]pyrimidin-4-yl]thio}propanoic acid and 3-{[5-(4-ethoxyphenyl)thieno[2,3-d]pyrimidin-4-yl]thio}propanoic acid (IC 50 values are 0.1 μM and 0.125 μM, respectively). Structure-activity relationships of 28 tested thienopyrimidine derivatives have been studied and binding mode of this chemical class has been predicted. Evaluation of the inhibitors on seven protein kinases revealed considerable selectivity towards CK2.

SUBSTITUTED AMINOPYRIMIDINES AS NEUROKININ ANTAGONISTS

The invention discloses tachykinin receptor antagonists. The tachykinin family of receptors comprising the neurokinins substance P (SP), neurokinin A, and neurokinin B and related neuropeptides that are widely distributed in the peripheral and central ner

THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS

The present invention provides thienopyrimidine compounds which are potasium channels inhibitors. Pharmaceutical compositions comprising the compounds and their use in the treatment of arrhythmia are also provided.